Adenocarcinoma of Colon Completed Phase 2 Trials for Oxaliplatin (DB00526)

Also known as: Adenocarcinoma Colon / Colon Adenocarcinoma / Adenocarcinoma of the Colon

Indication	Status	Phase
DBCOND0060083 (Adenocarcinoma of Colon)	Completed	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01703910	Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic	Treatment	Capecitabine (DB01101) Cetuximab (DB00002) Cisplatin (DB00515) Dasatinib (DB01254) Docetaxel (DB01248) Doxorubicin (DB00997) Erlotinib (DB00530) Etoposide (DB00773) Fluorouracil (DB00544) Gemcitabine (DB00441) Irinotecan (DB00762) Mitomycin (DB00305) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pemetrexed (DB00642) Raltitrexed (DB00293) Sorafenib (DB00398) Topotecan (DB01030) Vinorelbine (DB00361)
NCT00026234	Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver	Treatment	Capecitabine (DB01101) Dexamethasone (DB01234) Floxuridine (DB00322) Oxaliplatin (DB00526)
NCT00707889	Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer	Treatment	Bevacizumab (DB00112) Fluorouracil (DB00544) Leucovorin (DB00650) Linifanib (DB06080) Oxaliplatin (DB00526)